384 related articles for article (PubMed ID: 34035069)
1. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.
Smalley I; Chen Z; Phadke M; Li J; Yu X; Wyatt C; Evernden B; Messina JL; Sarnaik A; Sondak VK; Zhang C; Law V; Tran N; Etame A; Macaulay RJB; Eroglu Z; Forsyth PA; Rodriguez PC; Chen YA; Smalley KSM
Clin Cancer Res; 2021 Jul; 27(14):4109-4125. PubMed ID: 34035069
[TBL] [Abstract][Full Text] [Related]
2. Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance.
Smalley I; Law V; Wyatt C; Evernden B; Fang B; Koomen JM; Welsh EA; Macaulay RJB; Forsyth PA; Smalley KSM
Clin Cancer Res; 2020 May; 26(9):2163-2175. PubMed ID: 31924735
[TBL] [Abstract][Full Text] [Related]
3. Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases.
Weiss SA; Zito C; Tran T; Heishima K; Neumeister V; McGuire J; Adeniran A; Kluger H; Jilaveanu LB
J Neurooncol; 2021 Mar; 152(1):15-25. PubMed ID: 32974852
[TBL] [Abstract][Full Text] [Related]
4. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.
Erdag G; Schaefer JT; Smolkin ME; Deacon DH; Shea SM; Dengel LT; Patterson JW; Slingluff CL
Cancer Res; 2012 Mar; 72(5):1070-80. PubMed ID: 22266112
[TBL] [Abstract][Full Text] [Related]
5. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy.
Li J; Smalley I; Chen Z; Wu JY; Phadke MS; Teer JK; Nguyen T; Karreth FA; Koomen JM; Sarnaik AA; Zager JS; Khushalani NI; Tarhini AA; Sondak VK; Rodriguez PC; Messina JL; Chen YA; Smalley KSM
Clin Cancer Res; 2022 May; 28(10):2131-2146. PubMed ID: 35247927
[TBL] [Abstract][Full Text] [Related]
6. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
7. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
[TBL] [Abstract][Full Text] [Related]
8. Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.
Smalley KS; Fedorenko IV; Kenchappa RS; Sahebjam S; Forsyth PA
Int J Cancer; 2016 Sep; 139(6):1195-201. PubMed ID: 27084046
[TBL] [Abstract][Full Text] [Related]
9. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
Kluger HM; Zito CR; Barr ML; Baine MK; Chiang VL; Sznol M; Rimm DL; Chen L; Jilaveanu LB
Clin Cancer Res; 2015 Jul; 21(13):3052-60. PubMed ID: 25788491
[TBL] [Abstract][Full Text] [Related]
10. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Herrera-Rios D; Mughal SS; Teuber-Hanselmann S; Pierscianek D; Sucker A; Jansen P; Schimming T; Klode J; Reifenberger J; Felsberg J; Keyvani K; Brors B; Sure U; Reifenberger G; Schadendorf D; Helfrich I
Front Immunol; 2020; 11():120. PubMed ID: 32117271
[TBL] [Abstract][Full Text] [Related]
11. Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.
Alvarez-Breckenridge C; Markson SC; Stocking JH; Nayyar N; Lastrapes M; Strickland MR; Kim AE; de Sauvage M; Dahal A; Larson JM; Mora JL; Navia AW; Klein RH; Kuter BM; Gill CM; Bertalan M; Shaw B; Kaplan A; Subramanian M; Jain A; Kumar S; Danish H; White M; Shahid O; Pauken KE; Miller BC; Frederick DT; Hebert C; Shaw M; Martinez-Lage M; Frosch M; Wang N; Gerstner E; Nahed BV; Curry WT; Carter B; Cahill DP; Boland GM; Izar B; Davies MA; Sharpe AH; Suvà ML; Sullivan RJ; Brastianos PK; Carter SL
Cancer Immunol Res; 2022 Aug; 10(8):996-1012. PubMed ID: 35706413
[TBL] [Abstract][Full Text] [Related]
12. CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease.
Najem H; Marisetty A; Horbinski C; Long J; Huse JT; Glitza Oliva IC; Ferguson SD; Kumthekar PU; Wainwright DA; Chen P; Lesniak MS; Burks JK; Heimberger AB
Front Immunol; 2021; 12():745893. PubMed ID: 34691054
[TBL] [Abstract][Full Text] [Related]
13. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.
Fischer GM; Jalali A; Kircher DA; Lee WC; McQuade JL; Haydu LE; Joon AY; Reuben A; de Macedo MP; Carapeto FCL; Yang C; Srivastava A; Ambati CR; Sreekumar A; Hudgens CW; Knighton B; Deng W; Ferguson SD; Tawbi HA; Glitza IC; Gershenwald JE; Vashisht Gopal YN; Hwu P; Huse JT; Wargo JA; Futreal PA; Putluri N; Lazar AJ; DeBerardinis RJ; Marszalek JR; Zhang J; Holmen SL; Tetzlaff MT; Davies MA
Cancer Discov; 2019 May; 9(5):628-645. PubMed ID: 30787016
[TBL] [Abstract][Full Text] [Related]
14. Melanoma brain metastases: Biological basis and novel therapeutic strategies.
Phadke M; Ozgun A; Eroglu Z; Smalley KSM
Exp Dermatol; 2022 Jan; 31(1):31-42. PubMed ID: 33455008
[TBL] [Abstract][Full Text] [Related]
15. Melanoma brain metastases - Interdisciplinary management recommendations 2020.
Gutzmer R; Vordermark D; Hassel JC; Krex D; Wendl C; Schadendorf D; Sickmann T; Rieken S; Pukrop T; Höller C; Eigentler TK; Meier F
Cancer Treat Rev; 2020 Sep; 89():102083. PubMed ID: 32736188
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the treatment-naive ecosystem of human melanoma brain metastasis.
Biermann J; Melms JC; Amin AD; Wang Y; Caprio LA; Karz A; Tagore S; Barrera I; Ibarra-Arellano MA; Andreatta M; Fullerton BT; Gretarsson KH; Sahu V; Mangipudy VS; Nguyen TTT; Nair A; Rogava M; Ho P; Koch PD; Banu M; Humala N; Mahajan A; Walsh ZH; Shah SB; Vaccaro DH; Caldwell B; Mu M; Wünnemann F; Chazotte M; Berhe S; Luoma AM; Driver J; Ingham M; Khan SA; Rapisuwon S; Slingluff CL; Eigentler T; Röcken M; Carvajal R; Atkins MB; Davies MA; Agustinus A; Bakhoum SF; Azizi E; Siegelin M; Lu C; Carmona SJ; Hibshoosh H; Ribas A; Canoll P; Bruce JN; Bi WL; Agrawal P; Schapiro D; Hernando E; Macosko EZ; Chen F; Schwartz GK; Izar B
Cell; 2022 Jul; 185(14):2591-2608.e30. PubMed ID: 35803246
[TBL] [Abstract][Full Text] [Related]
17. Supportive roles of brain macrophages in CNS metastases and assessment of new approaches targeting their functions.
You H; Baluszek S; Kaminska B
Theranostics; 2020; 10(7):2949-2964. PubMed ID: 32194848
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
Di Giacomo AM; Margolin K
Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
[TBL] [Abstract][Full Text] [Related]
19. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features.
Raizer JJ; Hwu WJ; Panageas KS; Wilton A; Baldwin DE; Bailey E; von Althann C; Lamb LA; Alvarado G; Bilsky MH; Gutin PH
Neuro Oncol; 2008 Apr; 10(2):199-207. PubMed ID: 18287337
[TBL] [Abstract][Full Text] [Related]
20. Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment.
Steininger J; Gellrich FF; Engellandt K; Meinhardt M; Westphal D; Beissert S; Meier F; Glitza Oliva IC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
